April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Interest of Quantiferon®-tb Gold Test (cellestis) to Improve Etiologic and Therapeutic Work-Up in Uveitis
Author Affiliations & Notes
  • I. De Monchy
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • G. Gendron
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • G. Kaswin
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • N. Pogorzalek
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • H. Offret
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • M. Labetoulle
    Ophthalmology, Bicetre Hospital, Le Kremlin-Bicetre, France
  • Footnotes
    Commercial Relationships  I. De Monchy, None; G. Gendron, None; G. Kaswin, None; N. Pogorzalek, None; H. Offret, None; M. Labetoulle, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6032. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. De Monchy, G. Gendron, G. Kaswin, N. Pogorzalek, H. Offret, M. Labetoulle; Interest of Quantiferon®-tb Gold Test (cellestis) to Improve Etiologic and Therapeutic Work-Up in Uveitis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6032.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the usefulness of QuantiFERON®-TB Gold test (Cellestis) in patients with positive PPD (purified protein derivative) skin test for the etiologic and pre-therapeutic work-up of uveitis.

Results: : The mean age at the time of presentation was 56 years (+/- 2.2) and sex ratio (F/M) was 42%. Uveitis was bilateral in 42% of cases, and the location of inflammation was anterior in 35% of the cases, intermediate (23.5%), posterior (23.5%) or total (12%). One patient was referred for scleritis without ocular inflammation. The average of PPD test was 21.75mm (+/- 4mm) and minimal delay between PPD and quantiFERON®-TB Gold test was 3 days (mean: 42 days +/- 17). QuantiFERON®-TB Gold test was positive in 7 patients (58.3%) enjoining, after collaboration with internal medicine specialists, introduction of a full anti-tuberculosis therapeutic treatment in 6 patients (50%), that preceded oral steroids regimen in 33% of cases. Visual acuity increased dramatically (6 lines) in 3 patients and was unmodified for the others.

Keywords: clinical research methodology • uveitis-clinical/animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×